Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 8, 2001, Pages 2210-2214

  Bermudez, L E ^a   Inderlied, C B ^a   Kolonoski, P ^a   Wu, M ^a   Aralar, P ^a   Young, L S ^a  

^a Kuzell Institute for Arthritis and Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELITHROMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMANS; KETOLIDES; MACROLIDES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION;

EID: 0034920253     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.8.2210-2214.2001     Document Type: Article

References (22)

1. Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens
2. The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection
3. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial
4. Activities of Bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice
5. Activity of HMR3004 against Mycobacterium avium complex in vitro, in human macrophages and in beige mice
6. Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice
7. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy
8. Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex
9. Ketolides: New semisynthetic 14-membered ring macrolides
10. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS
11. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia
12. Epidemiology of infection by nontuberculous mycobacteria
13. In vitro and in vivo activities of clarithromycin against Mycobacterium avium
14. The Mycobacterium avium complex
15. In vitro and in vivo activity of azithromycin (CP 62, 993) against the Mycobacterium avium complex
16. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods
17. In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004
18. The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells
19. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease
20. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex
21. Cellular accumulation of the new ketolide RU 64004 by human neutrophils: Comparison with that of azithromycin and roxithromycin
22. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS